Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. - Wikidata - wikimedia - TriplyDB

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

http://www.wikidata.org/entity/Q33899917

about

Current Concepts in Multiple Sclerosis: Autoimmunity Versus Oligodendrogliopathy Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Rituximab for relapsing-remitting multiple sclerosis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Humoral-targeted immunotherapies in multiple sclerosis Multiple sclerosis: the role of cytokines in pathogenesis and in therapies Biomarkers of therapeutic response in multiple sclerosis: current status Neuroinflammation: Ways in Which the Immune System Affects the Brain Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials.Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.Aggressive multiple sclerosis: proposed definition and treatment algorithm.Safety of monoclonal antibodies for the treatment of multiple sclerosis.MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a.Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.Decreased Dicer expression is linked to increased expression of co-stimulatory molecule CD80 on B cells in multiple sclerosis Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis.Ethical challenges in paediatric clinical trials in multiple sclerosis Multiple sclerosis review.Defining Disease Activity and Response to Therapy in MS.Rituximab combination therapy in relapsing multiple sclerosis What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.Mechanisms of Regulatory B cell Function in Autoimmune and Inflammatory Diseases beyond IL-10.CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions Monoclonal antibodies as disease modifying therapy in multiple sclerosis.A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.Development of anti-CD20 therapy for multiple sclerosis.Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.The management of pediatric multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.Monoclonal antibodies in neuroinflammatory diseases.Drugs in development for relapsing multiple sclerosis.

P2860

Q22252578-717FCFB5-90C8-42AE-B39C-D982E029E521 Q24185806-7E22E92A-E3F9-4E5D-947F-FB0047F679DE Q24201928-056AD8DD-1E6F-4B78-8499-A5A9D0AE4443 Q24234454-9B53F9B5-2BAE-4178-B393-257F358A669C Q24234742-A0D292C1-E2AF-462F-823F-239D7050BA02 Q26776234-EE397A39-3058-4CB3-8A66-0AEB0266CBA8 Q26865971-A2D5F39D-0461-4A4A-9DB4-55DDF0475740 Q27011014-755BC015-1EDE-4974-A93A-5E8689688C26 Q27012726-BF298232-911B-4A7B-9E9C-1CD03EEC1694 Q28080620-4B87DDD4-9A92-46CD-A9D2-155E1F646F3C Q28534465-15365288-E65A-45CE-9A0A-C717679B1B25 Q30234672-E1EF8A75-16AF-4530-A938-5B7DAF18D13E Q31002774-5826438B-0D01-4E49-BAC5-BC6F3F5E4293 Q33634866-D69D92B1-6E5D-48E9-BD3D-9279B47F9136 Q33692520-9E2B9181-C9B0-4753-9FCA-F11DF6BA32BB Q34472457-1472E7F4-55B0-49DA-9F28-DD18850996AA Q34478828-A6EF3D65-BDA2-4B47-91BA-5FEEC4F50548 Q34542922-F3213CCD-7A23-47A1-9EFD-C97007246765 Q34980198-B432F6A4-50C0-4C21-AB61-A6AD3B5AB517 Q35606563-28A9EA05-F6ED-4F05-9299-3E2619CD52BF Q35689190-412D3C9E-7E6A-4099-AE3C-C3643DA91B51 Q35891605-A7DFEA76-0C95-4C07-83C3-796EA2F416FB Q35949329-868E6F52-5C9C-47A9-966F-415A6314FFD9 Q35958691-C87AB7B3-230D-4C5A-82A5-E426993D7BBF Q36357501-099BFBCE-E3E2-4309-BFCA-EB7EC5DF3806 Q36366897-A79B5519-439C-4405-B67B-8318D066C2D1 Q36396476-11C0C5A5-EA8A-4CE1-963A-8FF216975F65 Q36399264-7C51BAE2-5FC2-4318-8563-A4D4C559CEAF Q37628188-8CCEF432-87F5-448E-81D7-B0801EA7F9A9 Q37646434-4A9E358A-47ED-4029-B5EB-FE2CD2807EF7 Q37668086-5494A535-02ED-4446-B186-7FEDF8BED16E Q37818921-4D5260E1-760A-4C5E-8231-B3F379825684 Q37867728-A319AB87-0FF0-4CBB-9F05-94AA7951C0C9 Q37929621-359B0F16-8936-4A90-82AD-6F833788BC34 Q37968620-F07A31FA-FF38-4B20-A559-6A3544CEB356 Q38014263-3D7B0166-1464-401E-BE69-F8FEE56F8D01 Q38036853-95BA7421-8265-4363-95AB-06B8271E62AF Q38083041-454F1367-AE18-486E-B58B-9AB27D216A05 Q38092121-8ACA8555-4E8E-4B4F-896A-255D0AA85A08 Q38101004-406F7174-B7EA-4DF8-BC8C-61F10439290E

P2860

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

http://www.wikidata.org/entity/Q33899917

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rituximab add-on therapy for b ...... sis: a 52-week phase II trial.

@ast

Rituximab add-on therapy for b ...... sis: a 52-week phase II trial.

@en

type

label

Rituximab add-on therapy for b ...... sis: a 52-week phase II trial.

@ast

Rituximab add-on therapy for b ...... sis: a 52-week phase II trial.

@en

prefLabel

Rituximab add-on therapy for b ...... sis: a 52-week phase II trial.

@ast

Rituximab add-on therapy for b ...... sis: a 52-week phase II trial.

@en

P1433

Q33899917-4F0623DB-338B-4DEA-9A32-5C348A0B5E55

P1476

Q33899917-2B68C340-1E1F-44EF-AB20-6CFFCE9E0027

P2093

Q33899917-17952268-810B-4674-93D4-36B800D94B26

Q33899917-249B3A5A-3492-42AC-BA26-28A7A9AE99E0

Q33899917-43EA2C4E-8707-4760-AE22-C787554F2F31

Q33899917-54B9EF4E-DB3A-4F55-859B-947F78DE7A9E

Q33899917-64C31410-935A-4C08-9F74-1094F9F8E66E

Q33899917-65A049BA-49AD-4841-8243-545592B8819C

Q33899917-9E5C6626-8686-4298-B9F2-4A1D8AE89653

Q33899917-C3A94707-9AF6-49DB-B592-F0F4EAC74ED3

P2860

Q33899917-02E63C44-F59B-4A90-A81D-7E7415123271

Q33899917-0E459B04-D6BA-4456-9D2C-DCA525732DF8

Q33899917-1D550358-5CD5-4B28-903C-BEE8566BC1AA

Q33899917-26844977-8285-4F53-BD04-D101A00585F6

Q33899917-30DDF0F4-6302-4142-93BE-6BEA1B233191

Q33899917-3589FB04-34AF-45D0-8933-D5531B410F64

Q33899917-3E509DE8-10F4-4562-8847-1EF8EB91CF55

Q33899917-4160C7C7-BE4E-4800-880E-A6B1CD99F3F1

Q33899917-426CBD80-AAAB-4B40-9384-59CE748E1BA3

Q33899917-5A93E439-5FDB-486C-AA6B-EDA74C372F5B

P304

Q33899917-2C31868D-C234-41BF-A5C8-33EEA8DDD4A9

P31

Q33899917-3D58BB4C-DDE2-441B-810E-C7E84BB106E3

P356

Q33899917-C8AACA3B-63E6-438D-9D93-FD9FC262763D

P407

Q33899917-E154EAF9-6832-4B6E-9476-085B9BC870F3

P433

Q33899917-F769FC5E-0C24-42F9-AB4A-3D8DDAC7026B

P478

Q33899917-4C9D7F38-69C8-4F81-B0F7-763C10FE3A2E

P50

Q33899917-2E9ED2B4-CA1C-4FBB-86C5-87E980187C94

P577

Q33899917-9816E62E-8383-44D8-A0B0-9039BB8F967C

P698

Q33899917-4E11F636-6227-4D2F-B7E4-31503FE9E313

P921

Q33899917-E05A5BF5-CB8A-4D63-99AF-CDC8EF4288D6

Q33899917-E977B5B3-356B-4969-8D3E-BCA2A18D76CC

P932

Q33899917-0F07AD13-5E6B-4B4C-A1C2-5F71E7ABEC00

P356

WNL.0B013E3181E24373

P1433

P1476

Rituximab add-on therapy for b ...... osis: a 52-week phase II trial

@en

P2093

B J Parks

http://www.w3.org/2001/XMLSchema#string

J A Lyons

http://www.w3.org/2001/XMLSchema#string

J Lauber

http://www.w3.org/2001/XMLSchema#string

K Trinkaus

http://www.w3.org/2001/XMLSchema#string

L Piccio

http://www.w3.org/2001/XMLSchema#string

N T Tutlam

http://www.w3.org/2001/XMLSchema#string

R T Naismith

http://www.w3.org/2001/XMLSchema#string

S K Song

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

B cells and antibodies in CNS demyelinating disease.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors.

Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents.

P304

1860-1867

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3181E24373

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20530322

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multiple sclerosis

P932

2882224

http://www.w3.org/2001/XMLSchema#string